4.4 Article

Tauroursodeoxycholic Acid Attenuates Progression of Steatohepatitis in Mice Fed a Methionine-Choline-Deficient Diet

Journal

DIGESTIVE DISEASES AND SCIENCES
Volume 59, Issue 7, Pages 1461-1474

Publisher

SPRINGER
DOI: 10.1007/s10620-014-3217-0

Keywords

Fibrosis; Methionine and choline deficient diet; Nonalcoholic steatohepatitis; Tauroursodeoxycholic acid

Funding

  1. SNUH Research Fund [03-2012-0220]
  2. Daewoong research fund [06-2011-0070]

Ask authors/readers for more resources

Endoplasmic reticulum (ER) stress has been implicated in the development of nonalcoholic steatohepatitis. A methionine-choline-deficient (MCD) diet induces robust ER stress response and steatohepatitis, but the effects of ER stress modulation on the course of steatohepatitis remain uncertain. The present study evaluated whether reducing ER stress using the chemical chaperone tauroursodeoxycholic acid (TUDCA) could limit hepatocyte lipoapoptosis and progression of MCD diet-induced steatohepatitis. HuH7 cells stably transfected with sodium taurocholate cotransporting polypeptide (HuH-Ntcp cells) and palmitate (PA) were used. Experimental steatohepatitis was induced in male C57BL/6 mice using an MCD diet, and three different doses of TUDCA (500, or 1,000 mg/kg, once daily; or 500 mg/kg twice daily) were administered by gavage from the start of the MCD diet regimen or after 4 weeks. TUDCA reduced PA-induced ER stress as manifested by decreased eIF2 alpha phosphorylation, XBP1 splicing and expression of BiP, ATF4, and CHOP in HuH-Ntcp cells. TUDCA also decreased PA-induced JNK phosphorylation, Puma up-regulation and Bax activation, which in turn suppressed caspase-dependent hepatocyte lipoapoptosis. Mice given TUDCA did not show a significant decrease in the intrahepatic triglyceride contents and steatosis. However, TUDCA treatment significantly reduced hepatic damage compared to controls for both early and late treatment groups. TUDCA treatment reduced the expression of ER stress markers and pro-apoptotic proteins, leading to decreased apoptosis and oxidative stress. Finally, TUDCA reduced histological fibrosis along with the down-regulation of pro-fibrotic gene expression in both early and late treatment groups. These results show that TUDCA attenuates the progression of MCD diet-induced steatohepatitis by reducing ER stress.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Gastroenterology & Hepatology

Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis

Xianhua Mao, Ka Shing Cheung, Chengzhi Peng, Lung-Yi Mak, Ho Ming Cheng, James Fung, Noam Peleg, Howard H-W Leung, Rajneesh Kumar, Jeong-Hoon Lee, Amir Shlomai, Man-Fung Yuen, Wai-Kay Seto

Summary: This study collected data from observational studies to investigate the association of hepatic steatosis with HCC, cirrhosis, fibrosis, and HBsAg seroclearance. The results showed that hepatic steatosis was associated with an increased risk of HCC and cirrhosis among patients with CHB, but it also increased the chance of achieving a functional cure.

HEPATOLOGY (2023)

Article Biochemistry & Molecular Biology

Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis

Su Jong Yu, Jeong-Ju Yoo, Dong Ho Lee, Su Jin Kim, Eun Ju Cho, Se Hyung Kim, Jeong-Hoon Lee, Yoon Jun Kim, Jeong Min Lee, Jae Young Lee, Jung-Hwan Yoon

Summary: Gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced MRI can detect early stages of hepatocellular carcinoma (HCC) in patients with cirrhosis, but its survival benefit is unknown. This retrospective cohort study found that intermittent replacement of ultrasonography (USG) with Gd-EOB-DTPA-enhanced MRI improved the clinical outcomes of cirrhosis patients, including overall survival and time to progression.

BIOMEDICINES (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Effectiveness of US Surveillance of Hepatocellular Carcinoma in Chronic Hepatitis B: US LI-RADS Visualization Score

Min Kyung Park, Dong Ho Lee, Bo Yun Hur, Hyung-Chul Lee, Yun Bin Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee

Summary: This study assessed the detection power of ultrasound (US) and the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) based on the US Liver Imaging Reporting and Data System (LI-RADS) visualization score. The results showed that patients with suboptimal visualization (score B or C) had a higher risk of HCC and a higher rate of false-negative findings on US.

RADIOLOGY (2023)

Article Medicine, General & Internal

The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status in Korea: A nationwide population-based study

Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu

Summary: This study aimed to investigate whether the association between alcohol consumption and hepatocellular carcinoma (HCC) risk differs by fasting serum glucose level and diabetes. The results showed that mild-to-moderate alcohol consumption increased the risk of HCC in all glycemic statuses, but the risk was highest in patients with diabetes.

PLOS MEDICINE (2023)

Article Medicine, General & Internal

Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease

Jeong-Ju Yoo, Man Young Park, Eun Ju Cho, Su Jong Yu, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon

Summary: This study investigates the effect of smoking on the incidence of hepatocellular carcinoma (HCC) and cardiovascular disease (CVD) in patients with metabolic-associated fatty liver disease (MAFLD). The analysis of a Korean health screening database shows that smoking significantly increases the risk of HCC and CVD in MAFLD patients. Complete smoking cessation is highly recommended for individuals with MAFLD.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Oncology

Inverse Propensity Score-Weighted Analysis of Entecavir and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B: A Large-Scale Multicenter Study

Jihye Kim, Moon Haeng Hur, Seung Up Kim, Jin-Wook Kim, Dong Hyun Sinn, Hyun Woong Lee, Moon Young Kim, Jae Youn Cheong, Yong Jin Jung, Han Ah Lee, Young-Joo Jin, Jun Sik Yoon, Sung-Jae Park, Chang Hun Lee, In Hee Kim, June Sung Lee, Young Youn Cho, Hyung Joon Kim, Soo Young Park, Yeon Seok Seo, Hyunwoo Oh, Dae Won Jun, Mi Na Kim, Young Chang, Jae Young Jang, Sang Youn Hwang, Yoon Jun Kim

Summary: This study compared the effectiveness of entecavir and tenofovir disoproxil fumarate in preventing hepatocellular carcinoma among patients with chronic hepatitis B. The study found that the two antivirals had similar efficacy in preventing HCC and had comparable rates of other outcomes. However, the tenofovir disoproxil fumarate group had more side effects, leading to some patients needing to switch initial antiviral medications.

CANCERS (2023)

Article Oncology

Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects

Goh Eun Chung, Su Jong Yu, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho

Summary: This study investigates the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and cancer incidence or mortality. By categorizing MAFLD subgroups based on additional etiologies, the study found differential risks of all- and site-specific cancer incidence and mortality. These findings highlight the importance of MAFLD classification in identifying patients with poor cancer-related outcomes.

CANCER COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B

Cheol-Hyung Lee, Yun Bin Lee, Hyemi Moon, Jong-Won Chung, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung-Hwan Yoon

Summary: This study investigated the associations between aspirin use and risks of hepatocellular carcinoma (HCC), liver-related mortality, and major bleeding in non-cirrhotic patients with chronic hepatitis B (CHB). The results showed that aspirin use was associated with reduced risks of HCC and liver-related death, without an increase in the risk of major bleeding, in patients with CHB and a higher metabolic risk factor burden.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks

Scott K. Fung, Calvin Q. Pan, Grace Lai-Hung Wong, Wai-Kay Seto, Sang Hoon Ahn, Chi-Yi Chen, Hie-Won L. Hann, Maciej S. Jablkowski, Yoon Jun Kim, Cihan Yurdaydin, Cheng-Yuan Peng, Tuan Nguyen, Hiroshi Yatsuhashi, John F. Flaherty, Leland J. Yee, Frida Abramov, Hongyuan Wang, Dzhamal Abdurakhmanov, Young-Suk Lim, Maria Buti

Summary: Patients with CHB who switch from TDF to TAF show changes in lipid profiles but no significant impact on cardiovascular risk.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Biochemistry & Molecular Biology

A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma

Si-Cho Kim, Da-Won Kim, Eun Ju Cho, Jin-Young Lee, Jiwon Kim, Chaesun Kwon, Jeongsil Kim-Ha, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Won Kim, Woojin Kim, Hyunsoo Kim, Yoon Jun Kim, Jung-Hwan Yoon, Su Jong Yu, Young-Joon Kim

Summary: To address the limitations of current HCC surveillance tests, this study identifies two HCC-specific methylation markers, RNF135 and LDHB, and develops a highly sensitive PCR method, MS-HRM, to detect them in cfDNA. The combined analysis of RNF135 and LDHB outperforms the AFP test in detecting HCC.

MOLECULAR CANCER (2023)

Article Medicine, General & Internal

Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study

Heejoon Jang, Su Jong Yu, Hong Ghi Lee, Tae Min Kim, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim

Summary: The optimal duration of prophylactic antiviral therapy in patients with resolved HBV receiving rituximab is unclear. This study found that there is no significant difference in HBV reactivation between the 6-month and 12-month prophylactic TDF groups after completion of rituximab-based chemotherapy.

JOURNAL OF KOREAN MEDICAL SCIENCE (2023)

Article Medicine, General & Internal

Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients

Ji Min Han, Youngil Koh, Sung Hwan Kim, Sung Yun Suh, Yoon Sook Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Hye Sun Gwak

Summary: This retrospective study evaluated the records of liver cirrhosis patients receiving dalteparin for portal vein thrombosis treatment. No history of variceal bleeding and newly developed thrombus before treatment were predictive factors associated with increased treatment response. Delay in starting treatment (more than three months or six months) was associated with a higher risk of relapse. Individualized dosing regimen (based on body weight) was more effective than fixed dosing regimen, with no observed bleeding complications.

MEDICINA-LITHUANIA (2023)

No Data Available